Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Marinus (NASDAQ:MRNS) and Teva Pharma (NYSE:TEVA).
Marinus (MRNS)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Marinus, with a price target of $13. The company’s shares opened today at $6.09.
Yang commented:
“We do not see quarterly earnings as the most important matrix for a development stage biotech company. However, the severe postpartum depression (PPD) data readout is now expected in 4Q18 vs. previous guidance of 3Q18. This is due to slightly slower than anticipated enrollment. Management believes the delay is most likely measured by “weeks”, not “months” and seems confident about 3Q18 enrollment completion. Thus we anticipate the data readout is likely to be a mid 4Q18 event, not late 4Q18.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 24.1% and a 55.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $16.75, a 175.0% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $19 price target.
.
See today’s analyst top recommended stocks >>
Teva Pharma (TEVA)
In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Teva Pharma. The company’s shares opened today at $22.88.
McCarthy noted:
“Teva reported 2Q18 with revenues of $4.7B, just under consensus of $4.74B and non-GAAP EPS of $0.78 vs. $0.65. Expenses continued to decline reflecting execution of the restructuring plan with savings of ~$1B in 1H18. Guidance for 2018 was also raised (see below)…That’s the positives. The negatives? There is still the $30.2B in debt and the generics business, particularly in the US was off by nearly 1/3 from the same period in 2017, $947M vs. $1.33B. Copaxone too, $464M vs. $859M…Shares are down ~9%.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 11.0% and a 43.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Teva Pharma has an analyst consensus of Hold, with a price target consensus of $21.91, representing a -4.2% downside. In a report issued on July 18, Cantor Fitzgerald also assigned a Hold rating to the stock with a $25 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
